FFG
VRTX icon

Frisch Financial Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Frisch Financial Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,614
Closed -$719K – 168
2025
Q2 		$719K Buy
+1,614
New +$744K 0.18% 68

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Frisch Financial Group's VRTX Position: Q3 2025 in Review

Frisch Financial Group sold out of Vertex Pharmaceuticals (VRTX) in Q3 2025, closing a stake of 1,614 shares — an estimated $719K sold.

Frisch Financial Group first reported a position in VRTX in Q2 2025 and held it in 1 quarter. The position peaked at $719K in Q2 2025. 1,521 funds tracked by Wall St. Rank hold VRTX as of Q3 2025.

  • Frisch Financial Group reported no remaining Vertex Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Frisch Financial Group sold 1,614 Vertex Pharmaceuticals shares in Q3 2025, an estimated $719K.
  • Frisch Financial Group first reported a position in Vertex Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Frisch Financial Group's Vertex Pharmaceuticals position peaked at $719K in Q2 2025.
  • 1,521 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2025.

Based on Frisch Financial Group's 13F filing for Q3 2025, filed 10 Nov 2025.